| abstract |
The invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity against Pseudomonas aeruginosa, or a progeny bacteriophage thereof having a RFLP DNA profile substantially equivalent to MPK6. The MPK6 bacteriophage is capable of treating disease associated with Pseudomonas aeruginosa infection, including pneumonia, meningitis, peritonitis, sepsis, cystic fibrosis, otitis media, keratitis, endophthalmitis, bacteremia or burn wound infections. The invention also provides a method for screening agents for activity against Pseudomonas aeruginosa, comprising infecting Drosophila melanogaster with Pseudomonas aeruginosa, administering the test substance, and measuring either mortality or the number of colony forming units (CFUs) present in lysate of the infected Drosophila melanogaster. |